Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chromosome 6

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    222 result(s) found for: Chromosome 6. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-000208-34 Sponsor Protocol Number: CAMN107A2303 Start Date*: 2007-06-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III multi-center, open label, randomised study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chr...
    Medical condition: Adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009015 Chronic myeloid leukemia LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) BE (Completed) IT (Completed) ES (Completed) SK (Completed) AT (Completed) FR (Completed) NL (Completed) FI (Completed) DK (Completed) DE (Completed) PT (Prematurely Ended) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004323-37 Sponsor Protocol Number: BOS-IIG-01 Start Date*: 2015-03-24
    Sponsor Name:Fundación PETHEMA para el tratamiento de la leucemia y el linfoma
    Full Title: Single nucleotide polymorphism association with response and toxic effects in patients with Ph+ CP-CML treated with bosutinib after relapse or intolerance to previous treatment.
    Medical condition: Patients with chromosome Philadelphia positive (Ph+) in chronic phase mielogenus leukemia (CP CML)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022891 - Investigations 10034877 Philadelphia chromosome positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017775-19 Sponsor Protocol Number: CAMN107EIC01 Start Date*: 2010-05-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase IIIb, multicentre, open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase
    Medical condition: Newly diagnosed Philadelphia chromosome and/or BCR-ABL positive chronic myeloid leukaemia (CML) in chronic phase in adult patients
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052065 Chronic phase chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) BE (Completed) HU (Completed) ES (Completed) FI (Completed) GB (Completed) PT (Completed) DE (Completed) SE (Completed) CZ (Completed) DK (Completed) SK (Completed) GR (Completed) AT (Completed) LT (Completed) IT (Completed) LV (Completed) SI (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-021134-66 Sponsor Protocol Number: IJL-AFHT-TH10 Start Date*: Information not available in EudraCT
    Sponsor Name:Institut Jerome Lejeune
    Full Title: Efficacy assessment of systematic treatment with folinic acid and thyroid hormone on psychomotor development of Down Syndrome young children
    Medical condition: Down syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10044688 Trisomy 21 PT
    14.0 10010331 - Congenital, familial and genetic disorders 10013616 Down's syndrome LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004974-82 Sponsor Protocol Number: 2013.837 Start Date*: 2014-04-04
    Sponsor Name:Hospices Civils de Lyon
    Full Title: PETALS study : PEgylated interferon-alpha2a and TAsigna® for first Line therapy of Philadelphia chromosome-positive chronic phase CML patientS
    Medical condition: Chronic phase chronic myeloid leukaemia with Philadelphia chromosome positive or BCR-ABL positive
    Disease: Version SOC Term Classification Code Term Level
    19.1 10022891 - Investigations 10034877 Philadelphia chromosome positive PT
    19.1 100000004864 10052065 Chronic phase chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022946-25 Sponsor Protocol Number: AALL0622 Start Date*: 2011-12-19
    Sponsor Name:Children's Oncology Group
    Full Title: Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib: IND# 73969, NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)
    Medical condition: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000844 Acute lymphoblastic leukaemia LLT
    14.1 10022891 - Investigations 10034877 Philadelphia chromosome positive LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-002601-69 Sponsor Protocol Number: CA180-013 Start Date*: 2005-01-25
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase II Study to Determine the Activity of BMS-354825 in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease that is Resistant to High Dose Ima...
    Medical condition: Chronic phase Philadelphia chromosome-positive chronic myeloid leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) SE (Completed) FI (Completed) GB (Completed) IE (Completed) IT (Completed) BE (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-005712-27 Sponsor Protocol Number: CA180056 Start Date*: 2007-08-01
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL®) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects with Newly Diagnosed Chronic Phase Philadelphia Chrom...
    Medical condition: Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) GR (Completed) BE (Completed) NL (Completed) DE (Completed) AT (Completed) HU (Completed) ES (Completed) IT (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-004230-40 Sponsor Protocol Number: B1871006 Start Date*: 2006-02-17
    Sponsor Name:Wyeth Pharmaceuticals Inc., a wholly owned subsidary of Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA
    Full Title: A Phase 1/2 Study of SKI-606 in Philadelphia Chromosme Positive Leukemias
    Medical condition: Philadelphia Chromosome positive leukemias occur as a result of a reciprocal translocation between chromosomes 9 and 22. Its most common phenotype is Chronic Myelogenous Leukemia (CML), which has ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004848 10034877 Philadelphia chromosome positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) HU (Completed) AT (Completed) FI (Completed) SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022854-18 Sponsor Protocol Number: GMALL-PH-01 Start Date*: 2011-02-23
    Sponsor Name:Dekan des Fachbereichs Medizin der Goethe Universität, represented by the Coordinating Investigator
    Full Title: OPEN LABEL PHASE II STUDY TO EVALUATE THE SAFETY OF STANDARD INDUCTION AND CONSOLIDATION THERAPY IN COMBINATION WITH DASATINIB IN NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIV...
    Medical condition: Philadelphia chromosome positive Acute Lymphoblastic Leukemia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022945-52 Sponsor Protocol Number: ADVL0516 Start Date*: 2012-01-26
    Sponsor Name:Children’s Oncology Group
    Full Title: A Phase 1 Study of BMS-354825 (Dasatinib) in Children with Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia.
    Medical condition: Refractory solid tumors Ph+ leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    14.1 10022891 - Investigations 10034877 Philadelphia chromosome positive LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-004491-19 Sponsor Protocol Number: GMALL-MOLACT2-PONA Start Date*: 2020-09-15
    Sponsor Name:Universitätsklinikum Frankfurt
    Full Title: A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of ponatinib (Iclusig®) in adult patients with minimal residual disease (MRD) in Philadelphia-Chromosom...
    Medical condition: minimal residual disease (MRD) in Philadelphia-Chromosome positive acute lymphoblastic leukemia (Ph+ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080018 Philadelphia positive acute lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004278-40 Sponsor Protocol Number: CA180-597 Start Date*: 2015-11-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
    Medical condition: Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia / Castration-Resistant Prostate Cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-003359-19 Sponsor Protocol Number: GALPED1001 Start Date*: 2007-08-07
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: An open-label study of two single oral doses of galantamine, examining the pharmacokinetics, safety, and tolerability in children with Down syndrome
    Medical condition: Children with Down syndrom
    Disease: Version SOC Term Classification Code Term Level
    8.1 10013616 Down's syndrome LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006978-20 Sponsor Protocol Number: HBS407 Start Date*: 2007-11-21
    Sponsor Name:Talon Therapeutics , Inc.
    Full Title: A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo® (vincristine sulfate liposomes injection) in Adult Patients with Philadelphia Chromosome-negative Acute Lymphoblastic...
    Medical condition: Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001974-33 Sponsor Protocol Number: 08/014 Start Date*: 2009-04-14
    Sponsor Name:Radboud University Nijmegen Medical Centre [...]
    1. Radboud University Nijmegen Medical Centre
    2. Rotterdam Eye Hospital
    Full Title: mRNA-transfected dendritic cell vaccination in high risk uveal melanoma patients
    Medical condition: Our study population consists of HLA-A2.1 positive patients with a high risk uveal melanoma (stage II) with proven expression of melanoma associated antigens tyrosinase and/or gp100. Patients are i...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-004450-96 Sponsor Protocol Number: CA180-017 Start Date*: 2005-01-25
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Randomized Multi-center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have D...
    Medical condition: Chronic phase Philadelphia-Chromosome Positive (Ph+) Chronic Myeloid leukemia (CML)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) DE (Completed) HU (Completed) FI (Completed) GB (Completed) IE (Completed) DK (Completed) EE (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005694-21 Sponsor Protocol Number: EWALL-PH-01 (Graalphag06) Start Date*: 2007-06-29
    Sponsor Name:CH-Versailles
    Full Title: AN OPEN LABEL PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INDUCTION AND CONSOLIDATION THERAPY WITH DASATINIB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS AGED 55 YEARS AND OVER WITH PHIL...
    Medical condition: Philadelphia chromosome positive Acute Lymphoblastic Leukemia
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005101-31 Sponsor Protocol Number: AV001 Start Date*: 2014-06-17
    Sponsor Name:Pfizer Inc
    Full Title: A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
    Medical condition: Chronic Myeloid Leukemia (CML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) IT (Completed) SE (Completed) CZ (Completed) HU (Completed) SK (Completed) FI (Completed) NO (Completed) ES (Completed) DK (Completed) NL (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-004877-42 Sponsor Protocol Number: PETHEMA-BLIN-01 Start Date*: 2018-04-25
    Sponsor Name:FUNDACIÓN PETHEMA
    Full Title: A phase II, open-label study to evaluate the effect of blinatumomab administered during consolidation to reduce the level of minimal residual disease (MRD) assessed through flow cytometry in adult ...
    Medical condition: Acute lymphoblastic leukaemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 23:24:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA